Clinical Trials Logo

Inclusion Body Myositis clinical trials

View clinical trials related to Inclusion Body Myositis.

Filter by:

NCT ID: NCT00769860 Completed - Clinical trials for Inclusion Body Myositis

Arimoclomol in Sporadic Inclusion Body Myositis

Start date: September 2008
Phase: Phase 2/Phase 3
Study type: Interventional

Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over 4 months of treatment.

NCT ID: NCT00001261 Completed - Dermatomyositis Clinical Trials

Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies

Start date: May 1990
Phase: Phase 2
Study type: Interventional

Inflammatory myopathies are a group of muscle diseases characterized by muscle weakness, high levels of muscle enzymes in the blood, and inflammation of the tissue surrounding muscle fibers (endomysium). The diseases making up the inflammatory myopathies are grouped into three subsets: I) Polymyositis (PM) II) Dermatomyositis (DM) III) Inclusion Body Myositis (IBM) Inflammatory myopathies are thought to be autoimmune processes and are treated with steroids and immunosuppressive drugs. However, many patients who initially respond to these treatments develop resistance to the therapy or experience side effects causing the treatments to be stopped. Researchers believe that intravenous immunoglobulin (IVIg) may provide patients with PM, DM, and IBM a safer and more effective alternative to standard therapies for the diseases. IVIg is a drug that has been used successfully to treat other immune-related diseases of the nervous system. The study will take 60 patients and divide them into two groups. Group one will receive 2 injections of IVIg once a month for three months. Group two will receive 2 injections of placebo "inactive injection of sterile water" once a month for three months. Following the three months of treatment, group one will begin taking the placebo and group two will begin taking IVIg for an additional 3 months. The drug will be considered effective if patients receiving it experience a significant improvement (>15%) in muscle strength.